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Abstract: 
 
Spiroscytalin (1), a new tetramic acid that possesses an uncommon spiro-ring fusion between a 
polyketide-derived octalin ring system and a 2,4-pyrrolidinedione, along with two known 
compounds, leporin B (2) and purpactin A (3), were isolated from a solid phase culture of the 
fungus Scytalidium cuboideum (MSX 68345). The molecular connectivity of 1–3 was 
determined using NMR spectroscopy and mass spectrometry. The relative configurations 
of 1 and 2 were determined by NOESY experiments. The absolute configuration of 1 was 
determined by electronic circular dichroism (ECD) via a combination of experimental 
measurements and computational calculations. While leporin B was known, it displayed 
activities that had not been reported previously, including cytotoxicity against three human 
tumour cell lines and antibacterial activity against Candida albicans and Staphylococcus aureus. 
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Article: 
 
1. Introduction 
 
Ongoing studies on filamentous fungi as a source of anticancer leads1, 2 has provided our team 
with a view of the broad structural diversity that can be uncovered.3 Natural products from mixed 
biogenetic origin4, 5, 6, 7, 8 add to this chemical diversity, as they result from the merging of 
precursors from two distinct biosynthetic pools (i.e., acetylCoA and amino acids). Tetramic 
acids6 represent a good example, due to their heterocyclic 2,4-pyrrolidinedione ring system, and 
this compound class has displayed a variety of biological activities, ranging from HIV-1 
integrase inhibitors5 to antibacterial and antifungal activities4to cytotoxicity.6 These activities, in 
turn, have spawned further interest in discovering new members of the class9, 10 and paved the 
way for synthetic studies of natural products11, 12, 13 and derivatives thereof.14, 15, 16 A bioactivity-
directed purification study on a solid phase culture of Scytalidium cuboideum (MSX 68345) 
afforded three bioactive compounds, two of which were of mixed biogenetic origin. The new 
compound, spiroscytalin (1), was from the tetramic acid class, while one of the known 
compounds, leporin B (2), was an N-hydroxy-2-pyridone alkaloid;8, 17 the other known 
compound was purpactin A (3). 
 
 
 
2. Results and discussion 
 
Compound 1 was assigned the molecular formula C22H27NO2 via HRESIMS data (m/z338.2113 
for [M+H]+), establishing an index of hydrogen deficiency (IHD) of 10. The 1H NMR data 
(Table 1, Fig. S1) showed resonances for a monosubstituted aromatic ring (δH7.22–7.35 for H-17 
to H-21) as well as a methylene unit (δH 3.35 and 2.51 for H2-15) connected to it by virtue of 
HMBC correlations, suggestive of a phenylalanine moiety. Two olefinic protons were also 
observed (δH 5.77 and 5.34 for H-12 and H-13, respectively) as well as five methine protons 
(δH 3.78, 2.28, 1.90, 2.46, and 2.73 for H-3, H-6, H-7, H-11, and H-14, respectively), six more 
methylene protons (δH 1.38, 1.27; 1.49×2; and 1.78, 1.55 for H2-8, H2-9, and H2-10, 
respectively), and two methyl groups that were each doublets (δH 1.13 and 0.89, for CH3-7 and 
CH3-14, respectively). Finally, one NH proton was observed at δH 6.41. The 13C NMR data 
(Table 1) showed resonances for 22 carbons, supportive of the molecular formula, including 
signals for a ketone carbonyl (δC 212.2 for C-4), an amide/ester carbonyl (δC 177.2 for C-1), 
eight aromatic and olefinic carbons (δC132.5, 126.2, 136.6, 129.0×2, 129.3×2, and 127.5 for C-
12, C-13, C-16, C-17/C-21, C-18/C-20, and C-19, respectively), one nitrogen bearing carbon 
(δC 64.2 for C-3), one sp3 quaternary carbon (δC 59.0 for C-5), four methine carbons (δC 43.8, 
30.2, 31.6, 38.0 for C-6, C-7, C-11 and C-14, respectively), four methylene carbons (δC 28.5, 
19.6, 27.6 and 38.5 for C-8, C-9, C-10, and C-15, respectively), and two methyl carbons (δC 21.4 
and 16.2 for CH3-7 and CH3-14, respectively). COSY correlations from H-6 to H-7 and H-11, 
from H-11 to H-10 and H-12, from H-7 to CH3-7, and from H-14 to CH3-14, helped set-up the 
octalin (octahydronaphthalene) ring system (Fig. 1A). Moreover, COSY correlations from the 
NH proton to H-3, and COSY correlations, as well as coupling constants, between H2-15 and H-
3 established the tetramic acid moiety. The key HMBC correlations (Fig. 1A) from the NH 
proton to C-5 and C-15, from H-6 to C-1, C-4, C-3, C-7, CH3-7, C-10, and C-11, from H-13 to 
C-5, C-11, C-14, and CH3-14, as well as from CH3-14 to C-5, C-13, and C-14, suggested the 
spiro-ring juncture at C-5 between the octalin ring system and the 2,4-pyrrolidinedione ring 
system. The latter was a common structural motif in tetramic acids, of which many examples 
reside in the literature.6 Although uncommon, the spiro-ring fusion between a polyketide-derived 
octalin ring system and a 2,4-pyrrolidinedione ring system has precedent in a few compounds, 
such as spylidone7 and delaminomycins.18 Compound 1was ascribed the trivial name 
spiroscytalin. 
 
Table 1. NMR data for compound 1 (500 MHz for 1H, 125 MHz for13C; δ in ppm; CDCl3) 
Position δH, m (J in Hz) δC DEPT 
1 — 177.2 C 
3 3.78, dd (11.5, 3.0) 64.2 CH 
4 — 212.2 C 
5 — 59.0 C 
6 2.28, br d (6.3) 43.8 CH 
7 1.90, m 30.2 CH 
8 1.38, br d (13.2)/1.27, m 28.5 CH2 
9 1.49, m/1.49, m 19.6 CH2 
10 1.78, m/1.55, m 27.6 CH2 
11 2.46, m 31.6 CH 
12 5.77, dt (10.0, 3.0) 132.5 CH 
13 5.34, dt (10.0, 2.0) 126.2 CH 
14 2.73, m 38.0 CH 
15 3.35, dd (14.0, 3.0)/2.51, dd (14.0, 11.5) 38.5 CH2 
16 — 136.6 C 
17 7.22, d (7.5) 129.0 CH 
18 7.35, t (7.5) 129.3 CH 
19 7.29, d (7.5) 127.5 CH 
20 7.35, t (7.5) 129.3 CH 
21 7.22, d (7.5) 129.0 CH 
7-CH3 1.13, d (7.5) 21.4 CH3 
14-CH3 0.89, d (7.5) 16.2 CH3 
NH 6.41, s — — 
 
Fig. 1. A) COSY and selected HMBC correlations for compound 1. B) Key NOESY interactions 
from the ‘front’ and ‘back’ view (180° turn through the x-axis) observed in the spectrum of 1 as 
noted using the DFT (B3LYP/DGDZVP) minimum energy model for 1. 
 
Solving the relative configuration of 1 was somewhat challenging, leading to two possibilities 
(structures 1 or 4) that could fit the data. Due to overlapping signals in the 1H NMR spectrum, 
many of the J-values were not informative. However, a coupling constant of 6.3 Hz between H-6 
and H-11 suggested a cis-fused octalin ring system,19 and this was confirmed by a strong 
NOESY correlation between these two protons (Fig. 1B). Strong NOESY correlations were also 
observed between H-6 and H-14, indicating a 1,3-pseudodiaxial relationship. A proton 
decoupling experiment was performed to confirm the J-value between H-6 and H-7. Irradiation 
of H-11 resulted in H-6 remaining as a broad doublet (J=5.2 Hz), indicating 
a gauche relationship between H-6 and H-7; this finding was supported by a strong NOESY 
correlation between H-6 and CH3-7. The configuration at C-7 was enabled by a NOESY 
correlation between CH3-7 and H-11, indicative of a 1,3-diaxial relationship. Finally, a NOESY 
correlation between H-3 and CH3-14 suggested that they were on the same face of the molecule. 
At this stage, diastereomers 1 and 4 were both consistent with these NMR data, as were their 
respective enantiomers. Presumably, the configuration of the 2,4-pyrrolidinedione ring system 
depended upon whether an l- or d-phenylalanine was incorporated in the molecule. 
 
Compound 1 exhibited an UV profile similar to spylidone,7 and tetramic acids such as 
equisetin,5 phomasetin,5 and coniosetin4 have been shown to display consistent circular 
dichroism spectra. Thus, electronic circular dichroism (ECD) calculations were carried out to 
assign the absolute configuration using density functional theory (DFT).20, 21, 22, 23 Given the 
aforementioned relative configuration considerations, two distinct diastereoisomers were 
possible, either the 3R,5S (1) or 3S,5R (4). The respective enantiomers of these structures are 
also possible based on the data obtained, however, only structures 1 and 4 were utilized in the 
calculations since the ECD spectra would simply be antipodal for their enantiomers. Thus, a 
Monte Carlo conformational search, utilizing the MMFF94 molecular mechanics force field 
within a 5 kcal/mol energy window, led to three minimum conformers for each diastereoisomer. 
Reoptimization of the geometries of all conformers using DFT at the B3LYP/DGDZVP level, as 
implemented in the Gaussian 09 software, lead to the relative free energies and equilibrium 
Boltzmann-weighted populations of the diastereoisomeric series incorporating either 3R,5S-1 or 
3S,5R-4 (Fig. 2 and Tables S1 and S2). For further verification, calculations were also performed 
for the 3S,5S and 3R,5R diastereoisomers (data not shown); these two possibilities were ruled out 
because a NOESY correlation would not be possible from H-3 and CH3-14. The three energy 
minimized conformers for the 1 and 4 series were submitted to ECD calculations by time-
dependent density functional theory (TDDFT) at the B3LYP/DGDZVP level, considering the 
lowest 15 excited states with the CPCM solvent model for MeOH. The resulting ECD spectra for 
each series were energetically Boltzmann-weighted according to their respective conformational 
distribution and compared with the experimental ECD spectrum (Fig. 3 and Tables S1 and S2). 
The experimental ECD spectrum (Fig. 3) displayed a positive Cotton effect (CE) in the region of 
210–230 nm and a negative CE in the region of 260–300 nm. These data were in good agreement 
with the CE calculated for the 1 series. Therefore, the independent TDDFT calculation method 
supported the absolute configuration of 1 as (3R,5S,6R,7S,11R,14S), suggesting the incorporation 
of l-phenylalanine, which was consistent with biosynthetic considerations. 
 
 
Fig. 2. DFT (B3LYP/DGDZVP) geometry optimized conformers of 1 and 4 showing equilibrium 
population percentages (P) based on ΔG (Gibbs free energies relative to the absolute G value for 
the global minimum), assuming Boltzmann statistics at T=298.15 K and 1 atm. 
 
Compound 2 was assigned the molecular formula C22H25NO3 on the basis of HRESIMS data 
(m/z 352.1909 for [M+H]+), establishing an IHD of 11. The 1H and 13C NMR data (Fig. S2) 
of 2 matched that of a known compound leporin B,17 which is a 2-hydroxy-4-pyridone alkaloid 
and also of mixed biogenetic origin.6 Originally isolated from an unidentified fungal 
strain, 2 was reported as a transcription activator of hexokinase II gene, a possible target for the 
treatment of type 2 diabetes.24 We attempted to determine the absolute configuration of 2 via 
crystallography by making a bromobenzoyl analogue. However, this was unsuccessful due to 
paucity of material and the complex reactivity of the hydroxamate relative to a simple alcohol. 
Thus, relative configuration is shown for 2. 
 
 
Fig. 3. Comparison of the experimental ECD spectrum of 1 with the calculated ECD spectra of 
(3R,5S)-1 (1a–c series) and (3S,5R)-4 (4a–c series). 
 
Compound 3 was ascribed a molecular formula of C23H26O7 based on HRESIMS data 
(m/z437.1563 for [M+Na]+), indicating an IHD of 11. The 1H (Fig. S3) and 13C NMR and optical 
rotation data of 3 were in excellent agreement with those reported for purpactin A.25Purpactin A 
was first isolated from Penicillium purpurogenum and was reported to be an inhibitor of acyl-
CoA:cholesterol acyltransferase.25 
 
Compounds 1–3 were tested against three human tumour cells lines (Table 2). Compounds 1 
and 3 were moderately active in the human tumour panel (i.e., IC50 values between 10 and 20 
μM against all cell lines). The biological activity of the crude extract was likely due to leporin B 
(2), which displayed potent, sub μM activity against all three cell lines; cytotoxicity for 2 had not 
been reported previously. All three compounds were also tested for antimicrobial activity, and 2 
showed strong activities against Candida albicans and Staphylococcus aureus (with MIC values 
of 6.25 and 25 μg/mL, respectively). Studies are ongoing to increase the supply of 2, such that it 
can undergo more advanced testing. 
 
Table 2. Cytotoxicity against a panel of human tumour cell lines of compounds 1–3 
Compound IC50 values (in μM) 
MCF7 H460 SF268 
1 20.5 17.6 21.9 
2 0.2 0.1 0.2 
3 11.4 17.3 19.3 
Camptothecin 0.07 0.01 0.03 
 
3. Conclusion 
 
A series of compounds of mixed biogenetic origin were isolated and characterized from a fungal 
culture, including a new tetramic acid analogue (1). The biological activities were most 
promising for the known, yet sparsely studied fungal metabolite, leporin B (2). The biosynthetic 
machinery utilized by the fungus to produce such compounds is intriguing, especially from the 
standpoint of future studies to optimize the production of 2 and/or generate analogues via 
epigenetic manipulation of the growth conditions. 
 
4. Experimental 
 
4.1. General experimental procedures 
 
UV spectra and optical rotations were acquired on a Varian Cary 100 Bio UV–vis 
spectrophotometer and a Rudolph Research Autopol III polarimeter, respectively. NMR spectra 
were recorded on JEOL ECA-500, operating at 500 MHz for 1H and 125 MHz for 13C. 
HRESIMS was performed on a Thermo LTQ Orbitrap XL mass spectrometer equipped with an 
electrospray ionization source. HPLC was carried out using a Varian Prostar HPLC system 
equipped with ProStar 210 pumps and a Prostar 335 photodiode array detector, with data 
collected and analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2). 
For preparative HPLC, a YMC ODS-A (5 μm; 250×20 mm) column was used with a 10 mL/min 
flow rate; for the semi-preparative HPLC, a YMC ODS-A (5 μm; 250×10 mm) column was used 
with a 5 mL/min flow rate; for analytical HPLC, a YMC ODS-A (5 μm; 150×4.6 mm) column 
was used with a 1 mL/min flow rate (all from Waters). For analytical HPLC, a MetaTherm 
HPLC column temperature controller (Varian) maintained the temperature at 30 °C. 
 
4.2. Producing organism and fermentation 
 
Mycosynthetix fungal strain MSX 68345 was isolated by Dr. Barry Katz of MYCOsearch in 
1993 from leaf litter from a hardwood forest. The entire nuclear ribosomal ITS spacer region 
(ITS1-5.8S-ITS2)26 and first 600 bp of the nuclear ribosomal Large Subunit (LSU) rRNA gene 
were sequenced using methods outlined previously.27 Prior to BLAST search, the ITS region was 
edited using recent guidelines for establishing authenticity and reliability of ITS sequence 
data.28 A BLAST search with the NCBI GenBank database using the ITS region revealed close 
identity with isolates of S. cuboideum (GenBank AB213451; Identities=599/613 (98%), 
Gaps=11/613; GenBank AB213444.1; Identities=595/612 (97%). Gaps=13/612). S. 
cuboideum represents a new name for a previously described fungus (Arthrographis cuboidea) 
based on recent phylogenetic analyses using SSU, ITS and RPB2 sequences.29, 30 To confirm the 
identification of MSX 68345 using BLAST search, a Maximum Likelihood (ML) analysis was 
performed using RAxML.31 The combined ITS and LSU sequence of MSX 68345 was subjected 
to a BLAST search and aligned with taxa with highest affinity from the GenBank BLAST search 
as well as with other searches implemented through the Fungal Barcoding project 
(http://www.fungalbarcoding.org/). The ML analysis indicated that MSX 68345 was 
phylogenetically related to a clade consisting of several isolates of S. cuboideum, including the 
type strain (CBS 241.62; AB213451, GQ272628) with strong ML bootstrap support (Fig. S4). 
Based on results obtained through BLAST search and phylogenetic analysis, MSX 68345 was 
identified as S. cuboideum(Helotiales, Leotiomycetes, Pezizomycotina, Ascomycota). The 
combined ITS-LSU sequence was deposited in GenBank (Accession No. KR920748). 
 
The culture was stored on a malt extract slant and was transferred periodically. A fresh culture 
was grown on a similar slant, and a piece was transferred to a medium containing 2% soy 
peptone, 2% dextrose, and 1% yeast extract (YESD media). Following incubation (7 d) at 22 °C 
with agitation, the culture was used to inoculate 50 mL of a rice medium, prepared using rice to 
which was added a vitamin solution and twice the volume of rice with H2O, in a 250 mL 
Erlenmeyer flask. This was incubated at 22 °C until the culture showed good growth 
(approximately 14 d). The scale up culture was grown in a 2.8 L Fernbach flask containing 150 g 
rice and 300 mL H2O and was inoculated using a seed culture grown in YESD medium. This was 
incubated at 22 °C for 14 d. 
 
4.3. Extraction and isolation 
 
To the large scale solid fermentation was added 500 mL of 1:1 MeOH/CHCl3. The mixture was 
shaken for 24 h, filtered, and CHCl3 and H2O were added to generate a biphasic solution of 4:1:5 
(CHCl3:MeOH:H2O). The solution was stirred for 2 h, transferred to a separatory funnel, and the 
organic (lower) layer was removed. This organic extract was evaporated and defatted by 
partitioning between hexanes and CH3CN (1:1). The CH3CN partition (494 mg) was fractionated 
via flash chromatography using silica gel via a hexanes/CHCl3/MeOH gradient to afford six 
fractions. Fraction four (46.5 mg), which eluted with 0–5% MeOH in CHCl3 over 18 min, was 
separated further by reversed-phase HPLC (20:80–100:0% CH3CN–H2O over 100 min) to obtain 
eight fractions. Fraction two yielded purpactin A (3; 8.0 mg), fraction three yielded the new 
compound spiroscytalin (1; 2.4 mg), and fraction four yielded leporin B (2; 6.5 mg). Two more 
scale-ups of the same extract were processed in the same way outlined above to obtain the same 
compounds with the following combined yields: Compounds 1 (7.5 mg), 2 (20 mg), 
and 3 (16 mg). 
 
4.3.1. Spiroscytalin (1) 
 
White powder; [α]D25 −7.7 (c 0.01, MeOH); UV (MeOH) λmax (log ɛ)=376 (6.28); 1H, 13C NMR, 
and HMBC data, see Table 1; HRESIMS m/z 338.2113 for [M+H]+, calcd for C22H28NO2, 
338.2115. 
 
4.3.2. Leporin B (2) 
 
White powder; [α]D25 −67.7 (c 0.04, CHCl3); 1H NMR (500 MHz, CDCl3) δ 7.60, s (H-3), 7.41, 
m (H-18/H-22), 7.37, m (H-19/H-21), 7.29, m (H-20), 5.73, dq (J=16, 7; H-15), 5.37, ddq (J=15, 
8.6, 2; H-14), 4.82, dd (J=11, 9; H-13), 2.79, dd (J=10, 3.5; H-7), 1.77, m (H-8), 1.60, m (H-
9a/H-9b), 1.51, m (H-10a), 1.39, tq (J=3.5, 13; H-10b), 1.76, m (H-11a), 1.60, m (H-11b), 1.72, 
m (H-12), 1.71, dd (J=7, 2; H3-16), 0.86, d (J=6; H3-23); 13C NMR (125 MHz, CDCl3) δ 158.2 
(C-1), 129.2 (C-3), 111.2 (C-4), 157.6 (C-5), 113.7 (C-6), 38.1 (C-7), 35.9 (C-8), 35.8 (C-9), 
20.9 (C-10), 26.5 (C-11), 35.2 (C-12), 78.2 (C-13), 129.8 (C-14), 131.2 (C-15), 17.9 (C-16), 
133.7 (C-17), 129.1 (C-18/C-22), 128.3 (C-19/C-21), 127.5 (C-20), 20.4 (C-23); 
HRESIMS m/z 352.1909 for [M+H]+, calcd for C22H26NO3, 352.1907. 
 
4.3.3. Purpactin A (3) 
 
White powder; [α]D25 −46.1 (c 0.01, CHCl3); HRESIMS m/z 437.1563 for [M+Na]+, calcd for 
C23H26O7Na, 437.1571. 
 
4.4. Computational methods 
 
Theoretical calculations of TDDFT ECD spectra for compound 1 were performed with the 
Gaussian'03 program package.32 Geometry optimizations for diastereoisomers 1 and 4were 
carried out using the MMFF94 molecular mechanics force field calculations as implemented in 
the Spartan'08 program. A Monte Carlo search protocol33 was carried out considering an energy 
cutoff of 5 kcal/mol, and this generated two sets of conformers, which were made up of three 
conformers each (1a–1c and 4a–4c; Fig. 2). In each case, the minimum energy structures were 
filtered and checked for duplicity. No additional minimum energy structures were found. The 
conformers were optimized by DFT calculations at the B3LYP/DGDZVP level of theory, and 
thermochemical properties, IR, and vibrational analyses were performed at the same level. The 
self-consistent reaction field method (SCRF) with conductor-like continuum solvent model 
(COSMO) was employed to perform the ECD calculation of all conformers of 1- and 4-series in 
MeOH with the same basis set. The calculated excitation energy (in nm) and rotatory 
strength R in both dipole velocity (Rvel) and dipole length (Rlen) forms were simulated into an 
ECD curve by using the following Gaussian function: 
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where σ was the width of the band at 1/e height, and Ei and Ri were the excitation energies and 
rotatory strengths for transition i, respectively. σ=0.40 eV and Rvel were used. 
 
4.5. Cytotoxicity assay 
 
The cytotoxicity measurements against MCF-734 human breast carcinoma (Barbara A. Karmanos 
Cancer Center, Detroit, MI), NCI–H46035 human large cell lung carcinoma (HTB-177, American 
Type Culture Collection, Manassas, VA), and SF-26836 human astrocytoma (NCI Developmental 
Therapeutics Program, Frederick, MD) cell lines were performed as described previously.37 
 
4.6. Antimicrobial assay 
 
The compounds were screened for antimicrobial activity using an agar plate diffusion assay as 
described previously.38 
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Supplementary data 
 
Table S1. DFT (B3LYP/DGDZVP) atomic Cartesian coordinates (Å) for conformers 1 
Center 
number 
1a  1b  1c 
Coordinates (Angstroms)  Coordinates (Angstroms)  Coordinates (Angstroms) 
X Y Z  X Y Z  X Y Z 
1 6.567524 1.350420 0.219636  4.813565 2.620234 -1.352140  -4.444670 1.072015 -2.323266 
2 5.835402 0.572019 0.019002  4.681172 1.669064 -0.843203  -4.127263 0.693908 -1.354379 
3 3.949299 -1.429677 -0.478098  4.346913 -0.778317 0.476106  -3.319821 -0.300251 1.127900 
4 4.612305 0.576096 0.696925  3.610817 1.491832 0.034305  -3.435037 -0.520008 -1.274038 
5 6.119900 -0.435303 -0.912755  5.585774 0.621442 -1.067366  -4.418631 1.415348 -0.189795 
6 5.173045 -1.437885 -1.157666  5.413639 -0.604092 -0.404322  -4.014753 0.911903 1.053433 
7 3.651886 -0.425620 0.459751  3.423163 0.266175 0.709415  -3.014931 -1.031106 -0.033842 
8 4.405147 1.358106 1.424921  2.911950 2.306489 0.206560  -3.229708 -1.078640 -2.184881 
9 7.071011 -0.440656 -1.439267  6.422130 0.759159 -1.747794  -4.961907 2.355266 -0.249912 
10 5.387853 -2.226682 -1.874447  6.117715 -1.415126 -0.571074  -4.242596 1.461067 1.963908 
11 3.222234 -2.215587 -0.671757  4.232302 -1.723790 1.001376  -3.014406 -0.685901 2.098000 
12 2.317429 -0.399511 1.172947  2.273570 0.076103 1.663202  -2.270653 -2.343480 0.053544 
13 1.837478 -1.381459 1.137978  2.644160 -0.346594 2.607630  -2.463530 -2.822559 1.019073 
14 2.449125 -0.129109 2.226361  1.785942 1.028017 1.886946  -2.637159 -3.032817 -0.717475 
15 1.345778 0.645543 0.570178  1.218327 -0.909202 1.103929  -0.727475 -2.297053 -0.089779 
16 1.826518 1.636203 0.608757  1.706853 -1.885034 0.940861  -0.379688 -3.339236 0.002631 
17 0.000767 0.672233 1.300464  0.593242 -0.395413 -0.189007  -0.014226 -1.415453 0.937942 
18 -0.163818 1.187420 2.463971  1.275989 -0.336800 -1.284105  0.077240 -1.710010 2.182237 
19 0.932291 0.347757 -0.787235  0.049597 -1.068686 1.947140  -0.243826 -1.731139 -1.334563 
20 1.591214 0.240491 -1.550879  0.102269 -1.479694 2.873399  -0.553269 -2.054058 -2.244851 
21 -0.391285 0.443701 -1.038554  -1.146050 -1.053476 1.291796  0.830004 -0.918997 -1.234179 
22 -0.917835 0.330454 -2.146971  -2.225699 -1.335250 1.813771  1.455586 -0.435873 -2.179563 
23 -1.178949 0.797513 0.248646  -0.934916 -0.703372 -0.200973  1.247498 -0.727413 0.247179 
24 -1.720220 2.266518 0.158565  -1.253270 -1.950123 -1.105505  2.569544 -1.523600 0.535492 
25 -1.869173 2.566833 1.203686  -0.692056 -1.766724 -2.031495  2.540395 -1.713548 1.616292 
26 -2.349027 -0.157289 0.677123  -1.709343 0.545409 -0.767035  1.395199 0.735465 0.791159 
27 -2.655790 0.282334 1.633549  -1.312459 0.609882 -1.787644  1.593668 0.556205 1.854367 
28 -0.731384 3.279150 -0.448612  -0.739663 -3.289599 -0.544625  2.664710 -2.902760 -0.145103 
29 -1.153136 4.287109 -0.377382  -0.914920 -4.085316 -1.276523  3.576677 -3.407933 0.189534 
30 -0.534487 3.079578 -1.506732  -1.255695 -3.572281 0.378511  2.716100 -2.822093 -1.235591 
31 0.221781 3.287895 0.088121  0.336316 -3.260967 -0.347830  1.823057 -3.548986 0.118654 
32 -3.070347 2.348319 -0.523247  -2.716609 -2.045487 -1.480230  3.817198 -0.708673 0.264691 
33 -3.359454 3.336428 -0.882182  -3.050518 -3.019032 -1.841318  4.740968 -1.280221 0.170814 
34 -3.622793 -0.084269 -0.222462  -3.245207 0.351605 -0.943477  2.649532 1.513148 0.280754 
35 -4.450922 -0.378463 0.440736  -3.531802 1.049623 -1.745382  2.867241 2.242167 1.076564 
36 -3.908961 1.318070 -0.682438  -3.588104 -1.031926 -1.424691  3.854597 0.624429 0.160749 
37 -4.861031 1.478893 -1.189523  -4.622615 -1.200221 -1.726840  4.806406 1.116986 -0.041343 
38 -1.932933 -1.625801 0.986743  -1.365432 1.901835 -0.083987  0.106372 1.606538 0.730081 
39 -0.896944 -1.597656 1.346194  -0.329702 1.828825 0.270433  -0.747664 0.925282 0.806374 
40 -3.663198 -1.075323 -1.409848  -4.111123 0.736380 0.279411  2.446458 2.344336 -1.007626 
41 -2.962911 -0.745665 -2.181664  -3.978065 -0.011833 1.064991  2.370244 1.670054 -1.864668 
42 -4.667531 -1.040568 -1.851877  -5.166666 0.705946 -0.021347  3.340815 2.961887 -1.163410 
43 -3.319484 -2.507923 -0.983295  -3.755019 2.124267 0.827326  1.195748 3.228572 -0.935923 
44 -3.285443 -3.159736 -1.864919  -4.337882 2.327877 1.734243  1.046850 3.739399 -1.895267 
45 -4.109972 -2.906843 -0.334284  -4.034715 2.898220 0.100389  1.336121 4.017317 -0.185242 
46 -1.968997 -2.542548 -0.254162  -2.254500 2.210537 1.140202  -0.040777 2.386078 -0.594504 
47 -1.182159 -2.242273 -0.957361  -2.023932 1.506890 1.949658  -0.226568 1.684233 -1.416772 
48 -1.728858 -3.567715 0.054978  -2.001045 3.208770 1.519514  -0.930872 3.024586 -0.531042 
49 -2.776948 -2.198471 2.142951  -1.393107 3.052468 -1.109971  0.027221 2.544484 1.951367 
50 -3.848946 -2.211445 1.918933  -2.375530 3.178735 -1.577605  0.871815 3.239677 2.007404 
51 -2.638185 -1.606341 3.054701  -0.667643 2.874988 -1.912250  0.012488 1.968217 2.883620 
52 -2.475469 -3.228626 2.365426  -1.133105 4.003496 -0.630378  -0.889729 3.144170 1.916307 
 
 
Table S2. DFT (B3LYP/DGDZVP) atomic Cartesian coordinates (Å) for conformers of 4 
Center 
number 
4a  4b  4c 
Coordinates (Angstroms)  Coordinates (Angstroms)  Coordinates (Angstroms) 
X Y Z  X Y Z  X Y Z 
1 6.259734 1.340374 -1.191065  4.360166 2.689455 0.898675  -4.669305 -0.232220 2.000003 
2 5.591659 0.596757 -0.762857  4.288069 1.681868 0.495821  -4.196373 -0.303127 1.023160 
3 3.864959 -1.314086 0.316540  4.092093 -0.895584 -0.558569  -2.981891 -0.509720 -1.480751 
4 4.248412 0.562361 -1.152331  3.180454 1.321309 -0.281615  -3.198054 -1.259166 0.801846 
5 6.078007 -0.327533 0.171453  5.301890 0.750783 0.750887  -4.594426 0.552539 -0.011810 
6 5.209489 -1.284625 0.709019  5.199668 -0.541634 0.219315  -3.983246 0.444975 -1.266769 
7 3.363960 -0.392609 -0.618639  3.064070 0.028621 -0.818066  -2.572628 -1.374667 -0.451834 
8 3.885013 1.280235 -1.885454  2.399996 2.054223 -0.474631  -2.912166 -1.928978 1.609905 
9 7.122394 -0.304103 0.472817  6.163961 1.029460 1.352045  -5.375305 1.290260 0.156733 
10 5.577322 -2.009915 1.431007  5.984857 -1.270639 0.405637  -4.287721 1.100244 -2.079622 
11 3.200323 -2.066181 0.737149  4.030012 -1.898965 -0.976326  -2.518785 -0.589684 -2.462148 
12 1.901291 -0.401481 -1.017039  1.864798 -0.369712 -1.652367  -1.529991 -2.440196 -0.713543 
13 1.801952 -0.220781 -2.093154  1.336027 0.515438 -2.015615  -1.850789 -3.383878 -0.253435 
14 -0.266108 0.612255 1.689204  -1.475915 -1.649502 -1.306847  1.125510 -1.228154 1.569561 
15 -0.522140 0.591365 2.900394  -2.488116 -2.084997 -1.871560  1.595332 -1.146436 2.711134 
16 -0.774872 1.480011 -1.739083  0.530071 -0.652656 1.470459  1.119450 -0.953956 -2.003562 
17 -1.278526 0.781671 0.555786  -1.433987 -0.925451 0.038606  1.578829 -0.424235 0.348868 
18 -2.001172 2.156857 0.622577  -1.919010 -1.843773 1.196741  3.056971 -0.731071 -0.035445 
19 -2.682420 2.151606 1.487161  -3.002965 -1.997177 1.083100  3.709229 -0.321962 0.751228 
20 -2.393947 -0.326665 0.586959  -2.347058 0.352413 0.052068  1.503157 1.126372 0.606787 
21 -3.041975 -0.024292 1.418551  -3.364334 -0.052745 0.113988  2.376347 1.321411 1.240655 
22 -1.082354 3.380047 0.779283  -1.270790 -3.237029 1.256759  3.417014 -2.219809 -0.181143 
23 -1.680882 4.296476 0.816101  -1.689732 -3.808024 2.092248  4.484446 -2.324807 -0.402711 
24 -0.383181 3.465150 -0.055947  -0.189689 -3.170839 1.400471  2.857152 -2.694064 -0.990406 
25 -0.512370 3.321707 1.710857  -1.470807 -3.800077 0.340660  3.220191 -2.761852 0.748452 
26 -2.850000 2.242875 -0.614602  -1.705366 -1.066739 2.465763  3.336724 0.038247 -1.298010 
27 -3.054352 3.225897 -1.033892  -1.504100 -1.618739 3.381656  4.082250 -0.357896 -1.984825 
28 -3.275845 -0.255528 -0.698849  -2.130350 1.175460 1.360995  1.745232 1.920013 -0.712703 
29 -4.284856 -0.603188 -0.427989  -3.079133 1.683781 1.592111  2.204244 2.882933 -0.438376 
30 -3.428195 1.142662 -1.199895  -1.816803 0.299542 2.530166  2.722813 1.225707 -1.603488 
31 -4.023090 1.285995 -2.100122  -1.641894 0.790391 3.485973  2.955724 1.701528 -2.554622 
32 -1.939928 -1.779101 0.925590  -2.334620 1.243355 -1.226291  0.284956 1.664995 1.414750 
33 -1.068992 -1.713654 1.586495  -2.140519 0.594906 -2.087451  -0.032888 0.880615 2.109570 
34 -2.829943 -1.165912 -1.880855  -1.063125 2.305512 1.284507  0.469769 2.287502 -1.521452 
35 -1.922604 -0.756102 -2.333286  -0.064187 1.861354 1.260875  0.054269 1.383228 -1.974478 
36 -3.613959 -1.141645 -2.647415  -1.129097 2.902413 2.202368  0.760243 2.957062 -2.340608 
37 -2.567934 -2.602309 -1.420404  -1.260914 3.190701 0.050296  -0.585969 2.946550 -0.629414 
38 -2.216173 -3.199997 -2.269933  -0.463214 3.942044 0.007400  -1.486036 3.155435 -1.220230 
39 -3.502076 -3.065835 -1.078332  -2.205840 3.743373 0.129742  -0.220016 3.916064 -0.266468 
40 -1.518616 -2.610456 -0.303534  -1.243032 2.333650 -1.220061  -0.933449 2.020947 0.541927 
41 -0.582815 -2.210073 -0.710196  -0.258389 1.858913 -1.301801  -1.367588 1.100928 0.139072 
42 -1.307363 -3.638270 0.017347  -1.363117 2.963892 -2.110220  -1.701903 2.480874 1.175754 
43 -3.038814 -2.497884 1.737620  -3.733962 1.852632 -1.458239  0.722156 2.859574 2.289174 
44 -3.990431 -2.556836 1.197726  -4.068246 2.469912 -0.617173  1.124662 3.688812 1.696804 
45 -3.228422 -1.975529 2.681923  -4.481018 1.064731 -1.605268  1.497104 2.558221 3.002945 
46 -2.733050 -3.522642 1.977868  -3.735684 2.486422 -2.352509  -0.127460 3.248006 2.862572 
47 1.457375 -1.377652 -0.804460  2.208363 -0.925818 -2.534427  -1.471681 -2.633946 -1.789651 
48 -0.403045 0.771939 -0.698152  0.059609 -0.652059 0.245446  0.674776 -0.962383 -0.770807 
49 0.974468 0.494261 1.147413  -0.207937 -1.750573 -1.782438  0.112013 -2.057994 1.195560 
50 1.794399 0.440570 1.743656  -0.019049 -2.258429 -2.641110  -0.204695 -2.775753 1.840358 
51 1.071701 0.691919 -0.303861  0.864547 -1.279338 -0.897622  -0.074568 -2.195053 -0.254114 
52 1.555009 1.660932 -0.507868  1.425961 -2.144163 -0.510691  0.474261 -3.090529 -0.594712 
 
  
 
 
 
Fig. S1. 1H (top) and 13C (bottom) NMR spectra of compound 1 [500 MHz for 1H and 125 MHz 
for 13C; CDCl3]. 
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Fig. S2. 1H (top) and 13C NMR (bottom) spectra of compound 2 [500 MHz for 1H and 125 MHz 
for 13C; CDCl3]. 
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Fig. S3. 1H (top) and DEPTQ (bottom) NMR spectra of compound 3 [500 MHz for 1H and 100 
MHz for 13C; CDCl3]. 
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Fig. S4. Phylogram of the most likely tree (-lnL = 3472.03) from a RAxML analysis of 33 taxa 
based on complete ITS and partial region of the 28S large subunit nrDNA (1007 bp). Numbers 
refer to RAxML bootstrap support values ≥ 70% based on 1000 replicates. MSX 68345 is 
highlighted in gray and the Scytalidium cuboideum clade with 100% bootstrap value is highlighted 
yellow. Bar indicates nucleotide substitutions per site. 
 
